Signifier Medical Technologies Collaborates With Global Sleep Experts on Its Innovative Snoozeal® Device Clinical Trials

Signifier Medical Technologies today announced that it is partnering with twenty-seven Key Opinion Leaders in Sleep to test and build awareness around its Snoozeal® product in the lead up to its commercial launch. The company are innovators in the sleep-disordered breathing market

This research-focused initiative enhances Signifier Medical Technologies’ ability to fine-tune its revolutionary genioglossal muscle-neurostimulation technology and ensure that it meets the needs of patients around the world. It will also help refine internal commercial processes and ensure a seamless experience for future patients.

Key Opinion Leaders include top-tier physicians in key sleep therapeutic areas, including pulmonologists, cardiologists, neurologists and ear, nose and throat (ENT) specialists from leading health academies and institutions in North America, Europe and Australia. Signifier Medical Technologies is working with these medical professionals to build a large acceptance of the efficacy and the safety of this new technology and create a large multi-center clinical dataset that will further expand on the recent trials in Europe and United States.

Professor Atul Malhotra, Chief Investigator at the University of CaliforniaSan Diego for Snoozeal® mentioned the enthusiasm for having a new technology in this space. “I have been involved with the Snoozeal® device and have been doing ongoing research on this treatment. I am optimistic that this treatment will be an important treatment approach for patients with snoring and with mild sleep apnoea.”

“I have been very surprised by this device. The feedback and adherence from patients have been excellent, reporting an improvement in their snoring. The integration between the app and the device work is smooth, easy, and intuitive.” Dr. Peter M Baptista, MD, Ph.D. mentioned after using the device in some of his patients in Clínica Universidad de Navarra.

“We are pleased to work with professionals from some of the world’s top medical and academic institutions to revolutionize the sleep market,” said Prof Anshul Sama, co-founder, and CMO of Signifier Medical Technologies. “Our work together could impact the respiratory health of hundreds of millions of people and incorporates the latest and most innovative research in the field.”

These latest collaborations are an important step towards the global commercialization of Signifier Medical Technologies’ Snoozeal® product; currently commercially tested in the UK market.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”